AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05005325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group(Female)
Description: Hurdle steps Deep squats Inline lunges Shoulder Clearing Active straight leg raise Trunk stability pushup Rotary stability Spinal extension exam Spinal flexion exam
Study NCT05575570 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: EVAR
Description: EVAR stent graft and embolization material CE marked.
Study NCT05575570 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EVAR
Description: EVAR stent graft and embolization material CE marked.
Study NCT04469790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SIT+WALK
Description: Participants will interrupt their sitting for one week
Study NCT04469790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EX
Description: Participants will perform a single bout of exercise and then sit for the remaining time for one week
Study NCT06454305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active cycle of breathing technique
Description: Breathing control, thoracic expansion and forced expiratory training are the three components of ACBT. The purpose of the thoracic expansion phase is to facilitate the release of secretions, enhance ventilation, and supply the necessary volume for forced expiratory breathing. Secretions are moved into the central airways during the forceful expiratory exercise that follows The three stages of ACBT
Study NCT06454305 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blow Bottle Technique
Description: A 1-liter plastic bottle was filled with water to a height of 10 centimeters for this intervention. The water in the bottle was filled using a 30-cm-long tube that was placed 8 cm down. The participants were instructed to sit on a bed with comfortable position, Hold the bottle with one hand and the tube with the other Blowing Technique, Put the tube in mouth by holding lips firmly, Breath in through nose and out through mouth, Blowing enough water is bubbled, Short Breaks for 2 to 3 mints, When mucus rises up get out of it by coughing or huffing
Study NCT05088109 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: early mortality prediction using septic shock indices
Description: The Shock Index (SI) is the ratio of pulse rate to systolic blood pressure calculated by dividing pulse rate (beat/min) by systolic blood pressure (mm Hg). The adjusted shock index (ASI) is SI calculated after adjusting the heart rate according to body temperature that 10 beats will be added to the heart rate for every 1.0 °C rise in the body temperature above 37.0 °C. The modified shock index (MSI) is a ratio of heart rate to mean blood pressure (MAP). The DSI is a ratio of heart rate to diastolic blood pressure (DAP).
Study NCT05238649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant SARS-CoV-2 Fusion Protein Vaccine 10μg
Description: The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
Study NCT05238649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant SARS-CoV-2 Fusion Protein Vaccine 25μg
Description: The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
Study NCT05238649 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SARS-Cov-2 Vaccine Inactivated
Description: The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
Study NCT06034899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986196
Description: Specified dose on specified days
Study NCT04901845 — intervention group
Intervention type: OTHER
Intervention: No intervention provided
Description: Study is provided in the usual daily practice of the physicians without interventions made in their practice
Study NCT05172986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-up patient program
Description: An additional paramedical visit will be carried out before the surgery. The interview is carried out by the healthcare team. An organization within the service has been set up so that a nurse can be totally seconded for the RAAC mission. The consultation lasts 30 to 45 minutes.
Study NCT06485739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposomes combined with cisplatin/carboplatin
Description: Irinotecan liposomes 70mg/m2，use on the first day of each cycle The dosage of cisplatin and carboplatin is determined by the researchers
Study NCT06189989 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The group to which a care package was applied in addition to the clinical routine care protocol)
Description: Intervention Group:~* Immediately after the newborn's admission to the intensive care unit, mechanical ventilation mode, physiological parameters, blood gas results and descriptive characteristics of the baby were recorded in the Data Collection and Daily Monitoring Form.~* In addition to the routine care practices of the clinic (every 3 hours / 8 times a day), the newborn's temporary tachypnea care package was applied. Postural drainage, percussion and vibration were applied 4 times a day for an average of 10-15 minutes.~* Mechanical ventilation mode and physiological parameters were recorded one hour after 4 daily maintenance applications.~* Blood gas parameters were evaluated immediately before and 1 hour after the newborn was separated from mechanical ventilation.~* Physiological parameters were recorded again 1 hour after the first routine nursing care after the newborn was separated from mechanical ventilation.
Study NCT04178811 — intervention group
Intervention type: DEVICE
Intervention: Holmium Laser Enucleation of Prostate
Description: Use of Holmium Laser Enucleation of Prostate in management of Benign Prostatic Hyperplasia patients
Study NCT04967183 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Annual FIT
Description: Patients will be offered an annual FIT and colonoscopy will be performed if fecal hemoglobin concentration is ≥10µg / g of feces. After performing a colonoscopy the FIT will be sent to the patient:~* After one year if the unscheduled colonoscopy has been incomplete or a lesion requiring endoscopic surveillance has been completely resected.~* After five years if the colonoscopy has evaluated the entire mucosa, it is normal or with lesions that do not require endoscopic surveillance (1-2 non-advanced adenomas).
Study NCT04967183 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic surveillance.
Description: First surveillance colonoscopy will be performed in three-year time. If an advanced adenoma or at least three non-advanced adenomas are detected, colonoscopy will be repeated after 3 years. In contrast, if colonoscopy is normal or 1-2 non-advanced adenomas are detected, colonoscopy will be repeated after 5 years.
Study NCT06313554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib、Toripalimab、Gemcitabine、Oxaliplatin
Description: The first week dose of Surufatinib was 150mg, the second week and the subsequent cycle was 200 mg once a day (QD) orally, Q3W, and the drug was suspended for one day on the day of HAIC; Toripalimab: 240mg intravenous infusion d1, Q3W;~HAIC: All patients received HAIC treatment on D1. Hepatic arterial perfusion therapy (HAIC) : a treatment cycle every 3 weeks for 4-6 consecutive cycles:~Surufatinib and Toripalimab were administered continuously until intolerable toxicity, disease progression, withdrawal of informed consent, loss of follow-up, and investigator judgment that medication should be discontinued (whichever occurred first).
Study NCT05388422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of 3D scanner to measure physical size in patients with severe cerebral palsy
Description: Before starting the study, radiologic and clinical evaluation were performed. After measuring the patient's exact physical size by applying a 3D scanner, we manufacture hip brace in preventing progressive hip displacement in patients with severe cerebral palsy. After wearing for a week, follow-up radiologic and clinical evaluation were performed.
Study NCT05881122 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mad Dog Dietary Consultation
Description: The Mad Dog consultation was delivered in two parts over consecutive days. Part I entailed an accompanied trip to the participant's preferred grocery store to show the participant where selected foods could be found, how to read nutrition labels so that acceptable substitutions to the Mad Dog ingredients could be made, and how to shop for value when choices are presented. Part II of the consultation occurred in the participant's home and focused on meal preparation and kitchen accessibility, as well as a brief overview regarding the negative consequences of chronic inflammation, and the positive effects of adopting an anti-inflammatory diet. Questions and discussion were highly encouraged throughout the consultation and materials were left with the participants allowing them to easily review and reference information that was covered during the meeting. Specifically, participants were given 28 compliant recipes, additional snack ideas and shopping tips along with a consult summary.
Study NCT06006598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1584862
Description: BI 1584862
Study NCT06006598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BI 1584862
Description: Placebo matching BI 1584862
Study NCT06006598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: midazolam
Study NCT05326256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training- PSSE
Description: Barcelona Scoliosis Physical Therapy School (BSPTS) method exercises
Study NCT05326256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training- PSSE with vestibular exercises
Description: Vestibular exercises added to Barcelona Scoliosis Physical Therapy School (BSPTS) exercises
Study NCT05008471 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Formula nutrition
Description: The target energy of radiotherapy patients is recommended to be 25-30kcal/(kg·d), and the target energy of the intervention group should be increased by an additional 50% daily from the beginning of radiotherapy. Specifically, under the condition of ensuring the daily target energy 14kcal/(kg·d), formula nutrition should be added daily.
Study NCT05008159 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3 month community-based mobility and health intervention
Description: 12 weekly GROUP (10-15 adults per cohort) sessions + 3 INDIVIDUAL tailored system navigation sessions at beginning, midpoint, and end of program.~The 3-month GROUP program will include the following fixed components:~i) weekly interactive group-based health education sessions focused on:~* increasing knowledge, skills, and behaviours related to physical activity, healthy eating, and available community supports for older adults;~* socialization to foster peer and community connections, co-learning, and decrease social isolation~* skill-building to support independence and quality of life; and~ii) INDIVIDUAL tailored system navigation support
Study NCT04924140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aducanumab
Description: Administered as specified in the treatment arm
Study NCT04926506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiyanping injection
Description: Intramuscular injection of Xiyanping injection, 0.3mL / (kg.d) daily, Bid
Study NCT05077813 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: 13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB)
Description: A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
Study NCT05077813 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: 9 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB)
Description: A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 9 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
Study NCT05077813 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: All trans retinoic acid , Minocycline,Chicroic Acid and Vitamin D for (MDR-TB)
Description: Active Comparator: All trans retinoic acid , Minocycline,Chicroic Acid and Vitamin D 50 Subjects will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized All trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
Study NCT05077813 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: All trans retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)
Description: 50 Subjects with confection of COVID-19 and multidrug-resistant tuberculosis (MDR-TB) will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized All trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
Study NCT05077813 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: 13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)
Description: 50 Subjects with confection of COVID-19 and multidrug-resistant tuberculosis (MDR-TB) will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
Study NCT05077813 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: The standard therapy
Description: The standard therapy 100 infected patients with confection of COVID-19 and MDR-TB will receive the standard therapy for tuberculosis for 30 days
Study NCT06274151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen 500 Mg
Description: Attenuating the sub-acute inflammatory processes to monitor potential beneficial tissue healing following a muscle strain injury
Study NCT06274151 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Rehabilitation after muscle strain injury
Study NCT06274151 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Rehabilitation
Description: Rehabilitation after muscle strain injury
Study NCT06274151 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sub-acute inflammatory processes not attenuated. Group will be treated as control to monitor tissue healing following a muscle strain injury without pharmacological intervention.
Study NCT04715217 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CD22 CAR-T cells
Description: A autologous doping CAR - T cells injection targets with CD19 and CD22，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion CD19-CD22 CAR-T cells .
Study NCT04460963 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Adrenomedullin
Description: Adrenomedullin sample evaluation
Study NCT05461365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Gelfoam® cottonoids soaked in 40 IU of NPH insulin were placed on the nasal roof (between the nasal septum and the middle meatus) of each nostril. These remained in place for 15 minutes and were later removed. This procedure was performed in three visits one week apart. During the fourth and last visit (one week after the previous visit), olfaction was reevaluated using the measures previously described.
Study NCT04354168 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Application
Description: Nthabi mHealth Application delivers educational content and recommendations to minimize or eliminate health risks. The content is delivered via the Nthabi application downloaded on an Android phone smartphone. End-users can select from a list of topics relevant to the Lesotho population to engage with the conversational agent, Nthabi, and discuss conditions such as tuberculosis, HIV testing, healthy diet, and family planning.
Study NCT05742048 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: traumatic patient suspect to have long bone fracture between 18 - 65 years old
Description: Number of patients diagnosed to have a long bone fracture by using ultrasound. Number of patients diagnosed to have a long bone fracture by using x-ray . Comparison between Ultrasound bone scan result and X-ray imaging accuracy and sensitivity.
Study NCT05656885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens A
Description: Soft spherical hydrogel contact lens for 15 minutes
Study NCT05656885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens B
Description: Soft spherical silicone hydrogel contact lens for 15 minutes
Study NCT05742191 — intervention group
Intervention type: OTHER
Intervention: Daylight Savings time transitions
Description: Daylight Savings time transitions.
Study NCT04073797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inclisiran
Description: Inclisiran 284 mg, one injection
Study NCT04073797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran
Description: Inclisiran 284 mg, one injection
Study NCT04073797 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: 68Ga-DOTATATE PET-MRI
Description: 68Ga-DOTATATE PET-MRI at baseline and 12 weeks
Study NCT04073797 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 68Ga-DOTATATE PET-MRI
Description: 68Ga-DOTATATE PET-MRI at baseline and 12 weeks
Study NCT04073797 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATATE PET-MRI
Description: 68Ga-DOTATATE PET-MRI at baseline and 12 weeks
Study NCT04073797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Colchicine 500 mcg tablet once daily
Study NCT05930808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: First Test Concor (Fasted)
Description: Participants will receive single oral dose of Test Concor tablet under fasted or fed condition.
Study NCT05930808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: First Reference Concor (Fasted)
Description: Participants will receive single oral dose of Reference Concor tablet under fasted or fed condition
Study NCT05930808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: First Test Concor (Fed)
Description: Participants will receive single oral dose of Test Concor tablet under fasted or fed condition.
Study NCT05930808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: First Reference Concor (Fed)
Description: Participants will receive single oral dose of Reference Concor tablet under fasted or fed condition.
Study NCT05217355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBA-P01 (Botulinum toxin A)
Description: MBA-P01 will be injected into the Glabellar line